Accelerated Development On The Cards In EU and US For Bluebird, Celgene’s CAR-T Therapy
Executive Summary
Bluebird Bio and Celgene have secured a place on both the EMA’s PRIME scheme and the US FDA’s breakthrough therapy designation program for their multiple myeloma CAR-T therapy, bb2121. Meanwhile, Bluebird talks about how “incredibly helpful” PRIME has been with the development of LentiGlobin for beta-thalassemia.
You may also be interested in...
How Merck KgaA’s Life Science Unit Is Riding The Crest Of The Gene Therapy Wave
Udit Batra, member of Merck KGaA's executive board and CEO, life science, tells Scrip in an interview how the company is building on its play in the hot gene therapy area. Batra also outlines how the life science unit’s industry leading e-commerce platform already has the performance "of the level of Amazon or Alibaba" for the scientific space.
EMA Ends Year With Set of Straight Noes For PRIME Applicants
The European Medicines Agency rejected all seven eligibility requests for its priority medicines scheme that it reviewed in December.
Top Drugs To Watch At ASH 2017: CAR-T, Venetoclax Among Highlights
Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies, pivotal results moving major brands into bigger markets, PD-1 inhibitors branching out into new types of hematological malignancies and dueling gene therapies in hemophilia.